2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Tariffs, bold bets on cell therapy, and India’s vast manufacturing base reveal how geopolitics and ambition are reshaping production. The future of pharma supply chains hinges on resilience, innovation, and scale.
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
